

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* TAKEDA PHARMACEUTICAL CO LTD			2. Date of Event Requiring Statement (Month/Day/Year) 05/26/2021			3. Issuer Name and Ticker or Trading Symbol Day One Biopharmaceuticals, Inc. [DAWN]		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____			5. If Amendment, Date of Original Filed (Month/Day/Year)		
1-1, NIHONBASHI-HONCHO 2-CHOME								
(Street) CHUO-KU, TOKYO M0 103-8668			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person <input checked="" type="checkbox"/>					
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	6,470,382	I	See Explanation of Responses ⁽¹⁾⁽²⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person* TAKEDA PHARMACEUTICAL CO LTD		
(Last)	(First)	(Middle)
1-1, NIHONBASHI-HONCHO 2-CHOME		
(Street) CHUO-KU, TOKYO M0 103-8668		
(City)	(State)	(Zip)

1. Name and Address of Reporting Person* MILLENNIUM PHARMACEUTICALS INC		
(Last)	(First)	(Middle)
40 LANDSDOWNE STREET		
(Street) CAMBRIDGE MA 02139		
(City)	(State)	(Zip)

Explanation of Responses:

- This statement is being filed jointly by Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited's beneficial ownership of the reported securities is comprised of 6,470,382 shares of Common Stock held by Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. is a direct, wholly owned subsidiary of Takeda Pharmaceuticals U.S.A. Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a direct, wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

Remarks:

/s/ Yoshihiro Nakagawa, Corporate Officer, Global General Counsel of Takeda Pharmaceutical Company, Limited 05/26/2021

/s/ Paul Sundberg, Attorney-in-Fact for Millennium Pharmaceuticals, Inc. 05/26/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these present, that Millennium Pharmaceuticals, Inc. (the Reporting Person) hereby constitutes and appoints Paul Sundberg as the R

- 1) prepare, execute in the Reporting PersonTMs name and on the Reporting PersonTMs behalf, and submit to the U.S. Securities and Exchange C
- 2) prepare and file on behalf of the Reporting Person any and all reports, notices, communications and other documents (including, but not .
- 3) do and perform any and all acts for and on behalf of the Reporting Person which may be necessary or desirable to complete and execute an
- 4) complete for and on behalf of the Reporting Person, execute in the Reporting PersonTMs name and on the Reporting PersonTMs behalf, and si
- 5) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of l

The Reporting Person hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever
This Power of Attorney shall remain in full force and effect until the Reporting Person is no longer required to file any Reports with respect

IN WITNESS WHEREOF, the Reporting Person has caused this Power of Attorney to become effective as of the date set forth below.
MILLENNIUM PHARMACEUTICALS, INC.

By: /s/ Fabien Dubois
Name: Fabien Dubois
Title: Treasurer
Date: January 27, 2021